Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J R, Urmson"'
Publikováno v:
The Journal of laboratory and clinical medicine. 88(5)
Sequential studies in children with acute lymphoblastic leukemia have demonstrated that at diagnosis or relapse there is defective utilization of complement by the alternative pathway. Thus, the sera of 17/18 patients fail to completely consume C3 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6fb5a16a665813616596451de5a258cc
https://pubmed.ncbi.nlm.nih.gov/1068203
https://pubmed.ncbi.nlm.nih.gov/1068203
Publikováno v:
Gastroenterology. 76(6)
A prospective evaluation of the activity of the complement system was undertaken in 32 patients at the time of diagnosis of inflammatory bowel disease, before the onset of therapy. Serum classical pathway components and function were normal, while si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee9e14d1ea6d65ef0ccacff197f28115
https://pubmed.ncbi.nlm.nih.gov/437435
https://pubmed.ncbi.nlm.nih.gov/437435
Publikováno v:
The Journal of Immunology. 120:1799-1800
Sera from patients with acute lymphoblastic leukemia or active transplant rejection contain high concentrations of a material which regulates C3 and C3b activity. Preliminary isolation of this material reveals that it is able to interfere with both C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af00aefa8a6c0a27a42b363308fa2ed8
https://doi.org/10.4049/jimmunol.120.5.1799.d
https://doi.org/10.4049/jimmunol.120.5.1799.d
Publikováno v:
The Journal of Immunology. 116:1750-1750
Studies on patients with renal transplant rejection have revealed the presence of a circulating factor which stabilizes C3 and C3b. Thus, serum containing this material, in a concentration of 10%, will prevent C3 consumption when CoF, preformed C3b,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::239c61cac96ebd738bafb90d234a6314
https://doi.org/10.4049/jimmunol.116.6.1750.c
https://doi.org/10.4049/jimmunol.116.6.1750.c
Publikováno v:
The Journal of Immunology. 116:1751-1751
When activated properdin convertase () is added to serum, C3–C9 consumption occurs without Factors B or D. Only properdin is required. When zymosan is added to serum, PC is activated but C3–C9 consumption requires not only properdin but both Fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8fa3008d80b7b06d91d9edbad1e6dc5
https://doi.org/10.4049/jimmunol.116.6.1751.a
https://doi.org/10.4049/jimmunol.116.6.1751.a
Publikováno v:
The Journal of Immunology. 116:1751-1751
When activated properdin convertase () is added to serum, properdin is altered as manifested by a shift in electrophoretic mobility and a decrease in the extent of diffusion using the Mancini technique. Whether this latter observation represents comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c70a58889d41cf30a04546ec8938531
https://doi.org/10.4049/jimmunol.116.6.1751.c
https://doi.org/10.4049/jimmunol.116.6.1751.c
Publikováno v:
The Journal of Immunology. 116:1751-1751
The sera of 10 patients with membranoproliferative glomerulonephritis (MPGN) demonstrate levels of properdin (7/10) and properdin convertase (7/10) which are 3 standard deviations below the normal mean. These paired levels are significantly related (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d49afff3e07e47282d4b60e2db067e0d
https://doi.org/10.4049/jimmunol.116.6.1751.b
https://doi.org/10.4049/jimmunol.116.6.1751.b